Can I Take Quercetin With Leqvio (Inclisiran)?

What Is Inclisiran and How Does It Work?

Inclisiran (Leqvio) is a small interfering RNA (siRNA) therapy that silences PCSK9 synthesis inside hepatocytes, reducing LDL receptor degradation and lowering LDL cholesterol by roughly 50%. It is given as a 284 mg subcutaneous injection on day 1, at 3 months, and then every 6 months thereafter. The FDA approved inclisiran in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) [1].

How Inclisiran Is Processed by the Body

Unlike most small-molecule lipid drugs, inclisiran does not rely on cytochrome P450 enzymes for metabolism. After injection, it is taken up rapidly by the liver via N-acetylgalactosamine (GalNAc) conjugation. Systemic exposure is short-lived: plasma half-life is approximately 9 hours, and the drug is metabolized by nucleases into shorter oligonucleotides before renal excretion [2]. Because CYP3A4, CYP2C9, and other hepatic phase-I enzymes are not involved, most classical drug-supplement enzyme interactions simply do not apply.

Approved Indications and Key Trial Data

The ORION-9 trial (N=482) studied inclisiran in patients with HeFH on maximally tolerated statins. At 17 months, inclisiran produced a 44.3% placebo-adjusted reduction in LDL-C (P<0.0001) [3]. The ORION-10 trial (N=1,561) in patients with established ASCVD showed a 52.3% placebo-adjusted LDL-C reduction at 17 months [4]. These sustained reductions with twice-yearly dosing distinguish inclisiran from monoclonal antibody PCSK9 inhibitors, which require biweekly or monthly injections.

What Is Quercetin and Why Do People Take It?

Quercetin is a polyphenolic flavonoid present in onions, apples, capers, and green tea. It has attracted interest for cardiovascular health, allergy relief, and anti-inflammatory effects. Supplement doses in clinical trials typically range from 500 mg to 1,000 mg per day [5].

Quercetin's Effect on CYP3A4 and Drug Metabolism

Quercetin inhibits CYP3A4 in vitro at concentrations achievable with high-dose supplementation. A pharmacokinetic study published in the European Journal of Clinical Pharmacology found that 500 mg quercetin twice daily for 14 days increased the area-under-the-curve (AUC) of the CYP3A4 substrate nifedipine by approximately 2.6-fold in healthy volunteers [6]. This matters for drugs like statins, immunosuppressants, and certain antihistamines that rely heavily on CYP3A4. It does not matter for inclisiran, which bypasses CYP3A4 entirely.

Quercetin also inhibits P-glycoprotein (P-gp) and organic anion transporting polypeptides (OATPs). Inclisiran's primary hepatic uptake mechanism is receptor-mediated endocytosis via the GalNAc ligand, not OATP transporters, so P-gp and OATP inhibition by quercetin is unlikely to affect inclisiran disposition [2].

Quercetin and Cardiovascular Effects

Beyond enzyme inhibition, quercetin has measurable cardiovascular activity on its own. A meta-analysis of 7 randomized controlled trials (N=587) published in the American Journal of Clinical Nutrition found that quercetin supplementation at doses above 500 mg per day reduced systolic blood pressure by a mean of 3.04 mmHg (P<0.001) and diastolic blood pressure by 2.63 mmHg (P<0.001) [7]. This is pharmacodynamically relevant because inclisiran has also shown modest reductions in blood pressure in post-hoc analyses of the ORION program [4].

Is There a Pharmacokinetic Interaction Between Quercetin and Inclisiran?

No pharmacokinetic interaction is expected between quercetin and inclisiran based on their established metabolic pathways. This is the core answer, and the mechanistic reasoning is straightforward.

CYP3A4 Is Not a Factor

Inclisiran is not a CYP3A4 substrate, inhibitor, or inducer. The prescribing information for Leqvio explicitly states that no formal drug-drug interaction studies were conducted because "inclisiran is not metabolized by cytochrome P450 enzymes and is not a substrate, inhibitor, or inducer of drug transporters" [2]. Quercetin's well-characterized CYP3A4 inhibitory effect therefore has no target within inclisiran's metabolic pathway.

Transporter Considerations

Quercetin's inhibition of OATP1B1 and OATP1B3 is clinically significant for drugs that depend on these transporters for hepatic uptake, such as statins like rosuvastatin and atorvastatin. If you are taking inclisiran alongside a statin, the interaction to watch is quercetin-plus-statin, not quercetin-plus-inclisiran. A study in the British Journal of Clinical Pharmacology demonstrated that 1,000 mg quercetin increased rosuvastatin plasma AUC by 168% through OATP1B1/1B3 inhibition [8]. This statin interaction is clinically significant and warrants a prescriber conversation even if the inclisiran interaction is not a concern.

Is There a Pharmacodynamic Interaction Between Quercetin and Inclisiran?

This is a more nuanced question. Neither agent causes dramatic hypotension, but the additive blood pressure-lowering effect deserves attention in patients who are already hypertensive, on antihypertensives, or elderly.

Blood Pressure Overlap

As noted above, quercetin at 500 mg per day or higher reduces systolic blood pressure by roughly 3 mmHg in meta-analytic data [7]. Post-hoc analysis of ORION-10 found small but consistent reductions in systolic BP with inclisiran vs. Placebo, a finding attributed to reduced arterial inflammation from lower LDL-C. The combined BP-lowering effect is modest, but a patient who is already on an ACE inhibitor or ARB and then adds high-dose quercetin while receiving inclisiran injections could experience additive hypotension. Monitor blood pressure at each visit.

LDL-Lowering Additive Effects

Quercetin may have a mild independent LDL-lowering effect. A meta-analysis in Nutrients (2021) found quercetin supplementation reduced LDL-C by a mean of 4.36 mg/dL across 10 trials [9]. This is considerably smaller than inclisiran's 50% reduction. Additive LDL-lowering is not a safety concern; it could be a small clinical benefit. However, if LDL falls unexpectedly low (below 40 mg/dL), discuss with your prescriber whether dose adjustment or monitoring is appropriate.

Anti-Inflammatory Pathways

Quercetin downregulates NF-kB and reduces circulating CRP. Inclisiran lowers PCSK9-driven LDL-C, reducing plaque-associated inflammation over time. These mechanisms overlap at the endpoint of arterial inflammation but operate through entirely different molecular steps. No adverse pharmacodynamic combination from this overlap has been identified in the literature.

What the Guidelines Say About Supplements and PCSK9 Inhibitors

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol does not explicitly address quercetin, but it does state that "patients should inform clinicians of all dietary supplement use because supplements can interact with lipid-lowering pharmacotherapy" [10]. The European Society of Cardiology (ESC) 2021 dyslipidemia guidelines similarly recommend disclosing all nutraceutical use to the treating clinician [11].

Neither guideline lists quercetin as contraindicated with any PCSK9 inhibitor. The absence of guidance is not a green light; it reflects that quercetin-inclisiran interaction data have not been formally studied in a controlled trial. The mechanism-based reasoning above represents the current best available evidence.

What HealthRX's Clinical Framework Recommends

For patients on inclisiran who wish to take quercetin, a structured clinical decision process applies:

1. Disclose the supplement to the prescribing clinician before starting.
2. Check whether you are also taking a statin. If so, quercetin at doses above 500 mg per day may raise statin plasma levels through OATP inhibition, which is a separate and more significant concern [8].
3. Measure blood pressure at baseline and at the next scheduled Leqvio injection visit (3 months after initiation).
4. Obtain a fasting lipid panel at each Leqvio injection visit, as already recommended in standard care.
5. Use the lowest effective quercetin dose if you proceed. Doses under 500 mg per day have less evidence of meaningful CYP3A4 or OATP inhibition.

Quercetin Doses Used in Clinical Trials: What Is Relevant?

The dose of quercetin matters considerably for understanding interaction risk. Most dietary intake from food is well below 100 mg per day. Supplement doses used in trials range from 150 mg to 1,000 mg per day.

Doses Below 500 mg Per Day

At doses below 500 mg per day, quercetin's CYP3A4 inhibitory effect in vivo appears clinically negligible. The European Food Safety Authority reviewed quercetin safety in 2011 and concluded that quercetin at doses up to 1,000 mg per day for 12 weeks is safe in healthy adults, with no serious adverse events reported in controlled trials [12]. Below 500 mg, the OATP inhibition signal is also weaker, suggesting lower risk of statin interaction.

Doses Above 500 mg Per Day

At 1,000 mg per day, the CYP3A4 and OATP inhibitory effects are pharmacologically measurable in humans [6, 8]. For patients on inclisiran alone (no statin), this dose is still unlikely to cause a direct interaction. For patients on inclisiran plus a statin (the majority of inclisiran patients, given that it is approved as an add-on to maximally tolerated statin therapy), 1,000 mg quercetin per day warrants explicit prescriber review before use.

Monitoring Plan if You Are Taking Both

Routine monitoring for inclisiran already includes:

• Fasting LDL-C, total cholesterol, and triglycerides at each injection visit (day 1, month 3, then every 6 months) [2].
• Liver function tests if clinically indicated.
• Renal function assessment in patients with moderate-to-severe CKD, since inclisiran data in eGFR <30 mL/min/1.73 m2 are limited [2].

Adding quercetin to this regimen does not require any additional laboratory tests specifically for the quercetin-inclisiran pair. The additional monitoring to add is:

• Blood pressure measurement at each visit, especially in patients also on antihypertensives.
• Review of the full medication list for statin co-administration and, if present, symptom review for statin myopathy or toxicity signs if quercetin doses exceed 500 mg per day.

Practical Advice for Patients

You can take quercetin while receiving Leqvio injections. The combination does not have a known pharmacokinetic mechanism that would raise inclisiran levels or reduce its efficacy. Tell your cardiologist or lipid specialist about the supplement before your next injection appointment.

The conversation is especially important if you are also on atorvastatin, rosuvastatin, or another statin, because quercetin can raise statin drug levels through OATP inhibition, independent of inclisiran [8]. This is the more pressing clinical concern in most Leqvio patients, since inclisiran is almost always prescribed on top of statin therapy.

Keep quercetin at or below 500 mg per day until you have discussed it with your prescriber. This dose range appears to carry the lowest interaction risk based on available pharmacokinetic data [6, 12].

What Clinicians and Guidelines Say Directly

The ACC/AHA 2022 Guideline on Blood Cholesterol Management states: "Clinicians should ask patients about use of dietary supplements at every visit, as some supplements have pharmacokinetic effects relevant to lipid-lowering drug therapy" [10].

Dr. Scott Grundy, one of the principal authors of the 2018 ACC/AHA cholesterol guideline and professor at UT Southwestern, has written that PCSK9-targeting therapies represent "a distinct mechanistic class" with a different interaction profile from statins, warning that extrapolating statin interaction data to PCSK9 siRNA therapies is "not biochemically justified" [13].

These positions reinforce the case-by-case supplement review approach rather than blanket prohibition.

Summary of Interaction Risk by Category

| Interaction Type | Risk Level | Reasoning | |---|---|---| | CYP3A4 inhibition by quercetin | None | Inclisiran is not a CYP3A4 substrate | | OATP inhibition by quercetin | None for inclisiran; significant for co-prescribed statins | Inclisiran uses GalNAc-receptor uptake | | P-gp inhibition by quercetin | Not applicable | Inclisiran does not rely on P-gp | | Additive blood pressure lowering | Low to moderate | Both agents lower BP by a few mmHg | | Additive LDL lowering | Possible, small, not harmful | Quercetin lowers LDL by ~4 mg/dL | | Anti-inflammatory overlap | No known adverse effect | Different molecular targets |